Venkat Puja S, Smick Alexandra H, Salani Ritu
Department of Radiation Oncology, University of California Los Angeles.
Jonsson Comprehensive Cancer Center, University of California.
Curr Opin Obstet Gynecol. 2025 Feb 1;37(1):16-21. doi: 10.1097/GCO.0000000000000999. Epub 2024 Sep 26.
To review the recent updates in the management of cervical cancer across all stages of the disease.
After decades of minor advances, the landscape in cervical cancer is now rapidly changing. Recent studies have reported across the cervical cancer spectrum and on different therapeutic modalities. First, less radical surgery in the assessment and management of patients with early-stage, low-risk disease has been shown to be a safe option with reduced morbidity. The role of checkpoint inhibitor therapy in combination with chemotherapy and radiation has demonstrated improved survival outcomes, moving immunotherapy to earlier lines of therapy. The options for systemic therapy continue to include checkpoint inhibitors as well as treatment with antibody drug conjugates (ADCs) in the recurrent setting. Additional research continues to focus on targeting biomarkers in this disease.
In this paper, we will review the practice-changing trials impacting early stage, locally advanced, and recurrent cervical cancer patients. Despite advances, the limited survival for these patients continues to highlight the need for access to preventive healthcare (vaccine/cytology) and clinical trials to continue to make advances.
回顾宫颈癌各阶段治疗的最新进展。
经过数十年的微小进展，宫颈癌的治疗格局如今正在迅速改变。近期研究涵盖了宫颈癌的各个方面以及不同的治疗方式。首先，对于早期低风险疾病患者的评估和管理中，采用不太激进的手术已被证明是一种安全的选择，可降低发病率。检查点抑制剂疗法联合化疗和放疗已显示出改善生存结局，将免疫疗法提前至更早期的治疗方案。复发情况下的全身治疗选择继续包括检查点抑制剂以及抗体药物偶联物（ADC）治疗。更多研究继续聚焦于该疾病的生物标志物靶向治疗。
在本文中，我们将回顾影响早期、局部晚期和复发性宫颈癌患者的改变临床实践的试验。尽管取得了进展，但这些患者有限的生存率继续凸显获得预防性医疗保健（疫苗/细胞学检查）和开展临床试验以持续取得进展的必要性。
